文献速递淋巴瘤造血干细胞移植与细胞治疗

淋巴瘤高剂量治疗及自体干细胞移植后的晚期感染:一项丹麦人群研究

Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study.
PubMed 文献 · Br J Haematol · 2025-07-13

这项丹麦全国队列研究纳入781例淋巴瘤缓解期接受高剂量治疗及自体干细胞移植(HDT-ASCT)的患者和3905名按年龄、性别及合并症评分匹配的背景人群对照,比较90天后严重感染风险。中位随访7.7年,患者90天至2年严重感染发病率比为8.43(95%CI 6.98-10.16),2年累积风险患者23.7% vs 对照3.4%,严重感染风险升高持续至移植后10年。

要点

  • 患者90天至2年严重感染发病率比为8.43(95%CI 6.98-10.16),2年累积风险23.7%。
  • 对照2年累积风险3.4%(95%CI 2.9%-4.0%),患者严重感染风险升高持续至移植后10年。
  • 呼吸道感染最常见,2年累积风险差为10.9%(95%CI 8.6%-13.3%)。

核心结论

  • 淋巴瘤患者HDT-ASCT后90天起严重感染风险显著高于匹配的背景人群,且风险升高可持续至移植后10年。

研究设计与样本

  • 丹麦全国队列研究,纳入781例淋巴瘤缓解期接受HDT-ASCT的患者和3905名按年龄、性别及合并症评分匹配的背景人群对照。
  • 严重感染定义为需住院的感染;抗癌治疗和死亡作为竞争事件。

主要发现

  • 患者中位随访7.7年,90天至2年严重感染发病率比为8.43(95%CI 6.98-10.16)。
  • 2年严重感染累积风险患者为23.7%(95%CI 20.7%-26.7%),对照为3.4%(95%CI 2.9%-4.0%)。
  • 严重感染风险升高持续至HDT-ASCT后10年。
  • 呼吸道感染最常见,2年累积风险差为10.9%(95%CI 8.6%-13.3%)。
  • 患者在HDT-ASCT后5-10年更常被处方抗感染药物,包括广谱抗生素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infectious complications after high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for lymphoma are the leading cause of late non-relapse mortality. Characterizing the risk of infectious complications over time is important for rational follow-up and because alternatives to HDT-ASCT exist for some patients. This national cohort study investigated the risk of severe (defined by requiring hospitalization) late infections after 90 days among HDT-ASCT-treated patients with lymphoma in remission relative to the Danish background population (comparators) matched on age, sex and comorbidity score. Anti-cancer treatment after HDT-ASCT and death were competing events. This study included 781 patients and 3905 comparators. With a median follow-up of 7.7 years for patients, the incidence rate ratios of severe infections from 90 days until 2 years after HDT-ASCT was 8.43 (95% confidence interval (CI): 6.98-10.16) and the 2-year cumulative risk was 23.7% (95% CI: 20.7%-26.7%) for patients and 3.4% (95% CI: 2.9%-4.0%) for comparators. The risk of severe infections remained increased for up to 10 years after HDT-ASCT. Respiratory tract infections were the most frequent type, with a 2-year cumulative risk difference of 10.9% (95% CI: 8.6%-13.3%). Patients were more likely to be prescribed anti-infectives, including broad-spectrum antibiotics 5-10 years after HDT-ASCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Severinsen FT, Simonsen MR, Futtrup Maksten E, et al. Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study. Br J Haematol. 2025. PMID: 40653138. doi:10.1111/bjh.20262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。